Ce profil est validé par 2 label.

Company

AMONETA DIAGNOSTICS

EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Amoneta Diagnostics offers a blood diagnostic test to detect and follow the Alzheimer’s Disease pathology, which shall also be used as an optimizing method for present and future treatments and drug development projects.

Huningue, Grand-Est, France

Send a message

Anglais

AMONETA DIAGNOSTICS

Anglais

About News feed Dataroom

Amoneta offers a unique diagnostic test for an unmet, high medical need: Reliable early diagnosis of Alzheimer's Disease.

Amoneta offers a unique diagnostic test for an unmet, high medical need: Reliable early diagnosis of Alzheimer's Disease.

The test is performed on a minimal blood sample, based on the detection of two complementary biomarkers. The first results show a reliability up to 95% in human subjects, even 100% in animals. The competitive advantages of ADDIA test are (1) the ease of implementation, rapid, minimally invasive, effective laboratory routine and inexpensive, (2) reliability, compared to all existing competitor tests (3) repeatability, the fact that it can be repeated without bias, unlike neuropsychological tests.

Compared to competitor companies developing blood biomarkers, Amoneta is ahead as it is the only company so far with clinical development on 1024 patients being recruited in its late stage clinical studies.

1

Like

Our latest news

SCIENTIFIC AMERICAN - Need for new Biomarkers and a Blood-test for AD Diagnosis

Scentific American publishes ADDF President's article on the need for New Biomarkers to diagnose early Alzheimer in blood.

The Scientific American published an article written by Dr. ...

See more Réduire

SCIENTIFIC AMERICAN - Need for new Biomarkers and a Blood-test for AD Diagnosis

Scentific American publishes ADDF President's article on the need for New Biomarkers to diagnose early Alzheimer in blood.

The Scientific American published an article written by Dr. Howard Fillit, the Founding Executive Director and Chief Science Officer at the Alzheimer's Drug Discovery Foundation (ADDF), one of the most acknowledged Key Opinion Leaders in the field of Alzheimer's Disease.

The article points to the unmet need for blood biomarkers for an inexpensive and noninvasive clinical diagnosis of Alzheimer's Disease. According to Dr. Fillit, such a test would not only facilitate the diagnosis but also stimulate better treatments for the Alzheimer's Disease, for which (in sharp contrast to other illnesses and despite many efforts as well as huge expenses and hundreds of clinical trials), no new treatment have been approved in the past 16 years.

https://blogs.scientificamerican.com/observations/we-need-new-biomarkers-for-alzheimers-disease/

This article confirms, the real value of ADDIA, a blood diagnostic test based on a combination of 2 biomarkers. ADDIA is a multicentric proof-of-performance biomarker study, funded by the European Union Horizon-2020 Program.

slide 1 of 1, currently active

Team member(s)

Your request has been sent

Founder(s)

Employee(s)

Stephanie Boutillier

Project manager of ADDIA, AMONETA DIAGNOSTICS

Anglais

Join this organization

Your request has been sent

Team member(s)

Founder(s)

Employee(s)

Stephanie Boutillier

Project manager of ADDIA, AMONETA DIAGNOSTICS

Anglais

Our network

Your request has been sent

Join this network

Your message has been sent

Certifications

Alsace Business Angels

7 Entities

InvestHorizon - Accelerated

The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential. InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.

456 Entities

Communities

InvestHorizon

InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.

2680 Members

France Angels

France Angels is a Nationale Federation of Business Angels. Nationale federation that federates, represents and promotes French Business Angels.

491 Members

Our history

Start in 2014

2014

Amoneta Diagnostics SAS is founded by Firalis SA and SODIV.
2015

ADDIA Project proposal has been awarded with a "Seal of Excellence" and a 5 Mio € grant by the EU.
2016

Amoneta obtained approvals from various ethic committee for its ADDIA multicentric clinical study.
Jan-2017

Amoneta launched its ADDIA multicentric study aiming to do the proof-of-performance of its test.
Mar-2018

Strasbourg Hospital finalized recruitments for the Chronobiological study (part of ADDIA Program).

to be continued ...